New Products In Brief
This article was originally published in The Gray Sheet
Executive Summary
St. Jude EonC approval: St. Paul, Minn., firm announces FDA and EU approval of EonC, "the first extended-life primary cell (non-rechargeable) neurostimulator for chronic pain." Device features NeuroDynamix technology to deliver stimulation more efficiently, advanced programming capability to let patients adjust therapy strength in eight pain areas and constant current circuitry that automatically adjusts power output for consistent therapy over time, the company says. St. Jude gained the original Eon, approved in 2005, in its acquisition of Advanced Neuromodulation Systems later that year (1"The Gray Sheet" May 9, 2005, p. 16)